Niraparib exposure-response relationship in patients (pts) with newly diagnosed advanced ovarian cancer (AOC).

Authors

Bradley Monk

Bradley J. Monk

Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix, AZ

Bradley J. Monk , Ignacio Romero , Whitney Graybill , Cristina Churruca , David M. O'Malley , Bente Lund , Oi Wah S. Yap , Jean-Francois Baurain , Peter Graham Rose , Hannelore denys , Sharad A. Ghamande , Carmela Pisano , Michel Fabbro , Elena Ioana Braicu , Paula Calvert , Amnon Amit , Emily Prendergast , Ashley Milton , Zhi-Yi Zhang , Antonio Gonzalez Martin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT02655016

Citation

J Clin Oncol 38: 2020 (suppl; abstr 6051)

DOI

10.1200/JCO.2020.38.15_suppl.6051

Abstract #

6051

Poster Bd #

222

Abstract Disclosures